Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes

Daiichi Sankyo

Status and phase: Completed; Phase 3

Conditions: Type 2 Diabetes

Treatments: Drug: Colesevelam hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00151762

WEL-304

Details and patient eligibility

About

This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion/Rollover Criteria:

• Patients who have completed studies WEL-301, WEL-302, or WEL-303 with treatment compliance at least 80%
• Patients who have completed studies WEL-301, WEL-302, or WEL-303 who have not met withdrawal criteria